Verena Dederer

Max Von Laue Str. 15
Frankfurt Am Main, HE 60438, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

The structural basis for LRRK2's activation and autoinhibition.

The structural basis for LRRK2's activation and autoinhibition.

Journal: bioRxiv : the preprint server for biology

Published: June 12, 2026

The structural basis for LRRK2's activation and autoinhibition.

The structural basis for LRRK2's activation and autoinhibition.

Journal: bioRxiv : the preprint server for biology

Published: June 12, 2026

The structural basis for LRRK2's activation and autoinhibition.

The structural basis for LRRK2's activation and autoinhibition.

Journal: Cell

Published: November 21, 2025

Structure-Based Design, Synthesis, and Evaluation of Novel Ponatinib Derivatives With a Significantly Altered Selectivity Profile.

Structure-Based Design, Synthesis, and Evaluation of Novel Ponatinib Derivatives With a Significantly Altered Selectivity Profile.

Journal: ChemMedChem

Published: November 07, 2025

Covalent Targeting Leads to the Development of a LIMK1 Isoform-Selective Inhibitor.

Covalent Targeting Leads to the Development of a LIMK1 Isoform-Selective Inhibitor.

Journal: Journal of medicinal chemistry

Published: July 02, 2025

Type II kinase inhibitors that target Parkinson's disease-associated LRRK2.

Type II kinase inhibitors that target Parkinson's disease-associated LRRK2.

Journal: Science advances

Published: June 04, 2025

Selectivity profiles and substrate recognition of Rab-phosphorylating kinases.

Selectivity profiles and substrate recognition of Rab-phosphorylating kinases.

Journal: The Biochemical journal

Published: May 15, 2025

Native Taylor/Non-Taylor Dispersion-Mass Spectrometry (TNT-MS) Allows Rapid Protein Desalting and Multiplexed, Label-Free Ligand Screening.

Native Taylor/Non-Taylor Dispersion-Mass Spectrometry (TNT-MS) Allows Rapid Protein Desalting and Multiplexed, Label-Free Ligand Screening.

Journal: Small methods

Published: April 24, 2025

Type-II kinase inhibitors that target Parkinson's Disease-associated LRRK2.

Type-II kinase inhibitors that target Parkinson's Disease-associated LRRK2.

Journal: bioRxiv : the preprint server for biology

Published: November 18, 2024

Mechanism of human PINK1 activation at the TOM complex in a reconstituted system.

Mechanism of human PINK1 activation at the TOM complex in a reconstituted system.

Journal: Science advances

Published: June 07, 2024

A designed ankyrin-repeat protein that targets Parkinson's disease-associated LRRK2.

A designed ankyrin-repeat protein that targets Parkinson's disease-associated LRRK2.

Journal: The Journal of biological chemistry

Published: March 07, 2024

Inhibition of Parkinson's disease-related LRRK2 by type I and type II kinase inhibitors: Activity and structures.

Inhibition of Parkinson's disease-related LRRK2 by type I and type II kinase inhibitors: Activity and structures.

Journal: Science advances

Published: December 01, 2023

Showing 1-12 of 21

Last Updated: 09/26/2026